Progyny, Inc. Announces Third Quarter 2026 Results
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net Income
Selling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention
- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2026 (“the third quarter of 2026”), as compared to the three-month period ended September 30, 2025 (“the third quarter of 2025” or “the prior year period”).
“We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients,” said Pete Anevski, Chief Executive Officer of Progyny. “Beyond new sales activity, our season also focuses on renewing the existing base, where we once again achieved a near 100% retention for 2027 as well as strong demand from those accounts to expand their relationships with us through more comprehensive coverage and the further adoption of our newest services in pregnancy, parenting and menopause support.
“More than ever, these results once again affirm the critical importance of these benefits to employers,” continued Anevski. “We believe the energy and success we're seeing reflect how Progyny remains uniquely positioned to consistently deliver meaningful value and cost trend control to employers, which is particularly impactful given the pressures employers are facing from broader medical cost inflation.
“As we look into next year, we believe we're well-positioned to extend this momentum into 2027, as we're exiting the year with our strongest ever set-up in terms of our number of opportunities and the overall size and quality of the pipeline, as our demonstrated ability to effectively bend the cost curve positions us well for continued success.”
“We achieved strong top- and bottom-line growth this quarter, reflecting that member engagement was consistent with our expectations, and we are pleased to be in a position to raise the midpoint of our full year guidance,” said Mark Livingston, Chief Financial Officer of Progyny. “In addition to the strong results this quarter, we continued to maintain a high conversion of Adjusted EBITDA to operating cash flow, which has provided us with the flexibility to continue investing in our platform while also returning value to shareholders through the repurchase of nearly 11 million shares this year.” Third Quarter 2026 Highlights:
(unaudited; in thousands, except per 3Q 2026 3Q 2025 share amounts) Revenue $341,254 $313,346 Gross Profit $83,740 $72,835 Gross Margin 24.5% 23.2% Net Income $26,252 $13,864 Net Income per Diluted Share1 $0.32 $0.15 Adjusted Earnings per Diluted $0.52 $0.45 Share2 Adjusted EBITDA2 $58,439 $54,968 Adjusted EBITDA Margin2 17.1% 17.5% Trailing Twelve-Month Operating Cash $207,182 $208,153 Flow
1. Net income per diluted share reflects weighted-average shares outstanding as adjusted for potential dilutive securities, including options, restricted stock units, and shares issuable under the employee stock purchase plan . 1 2. Adjusted Earnings per Diluted Share, Adjusted EBITDA, and Adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Please see Annex A of this press release for a reconciliation of Adjusted Earnings per Diluted Share to earnings per share, and Adjusted EBITDA to net income, the most directly comparable financial measures stated in accordance with GAAP for each of the periods presented. We calculate Adjusted Earnings per Diluted Share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the impact of taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue.
Revenue was $341.3 million, an 8.9% increase as compared to the $313.3 million reported in the third quarter of 2025, due to an increase in the number of clients and covered lives.
• Fertility benefit services revenue was $223.4 million, a 10.6% increase from the $201.9 million reported in the third quarter of 2025.
• Pharmacy benefit services revenue was $117.9 million, a 5.8% increase as compared to the $111.4 million reported in the third quarter of 2025.
Gross profit was $83.7 million, an increase of 15% from the $72.8 million reported in the third quarter of 2025, reflecting ongoing efficiencies realized in the delivery of our care management services as well as a decrease in stock- based compensation expense . Gross margin was 24.5%, as compared to 23.2% reported in the prior year .
Net income was $26.3 million, or $0.32 income per diluted share, as compared to the $13.9 million, or $0.15 income per diluted share, reported in the third quarter of 2025. The higher net income was due primarily to the higher gross profit and lower stock-based compensation expense, which was partially offset by lower interest and other income, net.
Adjusted EBITDA was $58.4 million, an increase of 6.3% as compared to the $55.0 million reported in the third quarter of 2025, as the higher gross profit was partially offset by planned investments to expand the features and functionality of our platform . Adjusted EBITDA margin was 17.1% as compared to the 17.5% Adjusted EBITDA margin in the third quarter of 2025. Refer to Annex A for a reconciliation of Adjusted EBITDA to net income.
Net cash provided by operating activities in the third quarter of 2026 was $56.6 million, as compared to $50.7 million in the prior year period. Cash flow reflects the timing impact of certain working capital items in both periods.
As of September 30, 2026, the Company had total working capital of approximately $224.4 million and no debt. This included cash and cash equivalents and marketable securities of $195.6 million, a decrease of $41.3 million from the balances as of June 30, 2026, as the operating cash flow generated was offset by share repurchase activity during the quarter. The Company's $200 million revolving credit facility remains undrawn, and the Company has no planned use for the facility at this time.
During the third quarter of 2026, the Company repurchased nearly 3 million shares of its common stock for a total cost of $82.7 million through its May 2026 share repurchase program, which provided for a total authorization of up to $200 million. To date, the Company has repurchased nearly 5.5 million shares of its common stock under this most recent program, and approximately $51 million remains under the existing authorization. In combination with its predecessor program which began in November 2025 and concluded earlier this year, the Company has now repurchased nearly 11 million shares thus far in 2026, and approximately 14.3 million shares overall since November 2025.
The Company had 607 fertility and family building clients as of September 30, 2026, as compared to 553 clients as of September 30, 2025. 2
* Represents the number of ART cycles performed, including IVF with a fresh embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers, and egg freezing. Includes ART cycles performed in the first half of 2025 under the extended transition of care agreement with the large client who did not renew its service agreement.
** Represents the member utilization rate for all fertility and family building services, including, but not limited to, ART cycles, initial consultations, IUIs, and genetic testing. The utilization rate for all members includes all unique members (female and male) who utilize the benefit during that period, while the utilization rate for female only includes only unique females who utilize the benefit during that period. For purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period. Individual periods cannot be combined as member treatments may span multiple periods. Utilization for the nine month period in 2025 excludes activity under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement, as only members meeting certain criteria were eligible to use the benefit.
***Includes approximately 300,000 members from a single client who are not reflected in utilization as a result of the client's chosen benefit design. 2025 excludes the limited number of members who were eligible to use the benefit under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement.
As the fourth quarter begins, member activity continues to remain healthy. In light of the strong results over the first nine months of the year, as well as our expectations for member engagement over the remainder of the year, we're raising the midpoint of our full year guidance.
The majority of the clients and lives added in the most recent selling season are expected to go live in the first quarter of 2027, though a meaningful number of lives are expected to launch mid-year. In addition, a number of the newest clients have already launched their benefit in 2026. Once all new clients are live in 2027, the Company anticipates having in excess of 660 clients, representing approximately 8.3 million covered lives.
As it relates to 2027, consistent with past practice, the Company anticipates providing financial guidance when it reports its year-end results in February. The Company is providing the following financial guidance for both the three- month and full year periods ending December 31, 2026.
o Revenue is projected to be $1.365 billion to $1.385 billion, reflecting growth of 5.9% to 7.5%; excluding the $48.5 million of revenue in 2025 from the large client who was under a transition agreement in the first half of 2025, revenue is expected to increase by 10.1% to 11.7% o Net income is projected to be $107.0 million to $110.6 million, or $1.30 to $1.35 per diluted share, on the basis of approximately 82.0 million assumed weighted-average fully diluted-shares outstanding o Adjusted EBITDA 1 is projected to be $235.0 million to $240.0 million
o Revenue is projected to be $344.7 million to $364.7 million, reflecting growth of 8.3% to 14.6% o Net income is projected to be $28.5 million to $32.1 million, or $0.36 to $0.41 per diluted share, on the basis of approximately 79.0 million assumed weighted-average fully diluted-shares outstanding o Adjusted EBITDA 1 is projected to be $57.9 million to $62.9 million
1. Adjusted EBITDA and Adjusted earnings per diluted share are financial measures that are not required by, or presented in accordance with, GAAP. Please see Annex A of this press release for a reconciliation of forward-looking Adjusted EBITDA to forward-looking net 3 income and Adjusted net income to net income, the most directly comparable financial measures stated in accordance with GAAP, for the period presented.
Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 p.m. Pacific Time) today, November 4, 2026, to discuss its financial results. Interested participants from the United States may join by calling 1.866.825.7331 and using conference ID 265484. Participants from international locations may join by calling 1.973.413.6106 and using the same conference ID. A replay of the call will be available until November 11, 2026 at 5:00 p.m. Eastern Time by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and entering passcode 265484. A live audio webcast of the call and subsequent replay will also be available through the Events & Presentations section of the Company’s Investor Relations website at investors.progyny.com.
Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx®, and personalized guidance from Progyny Care Advocates® to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, are forward-looking statements including, without limitation, statements regarding our financial outlook for the fourth quarter and full year 2026, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2026; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2027 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues, ” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.
Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, 4 regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov .
Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release and the accompanying tables include the non-GAAP financial measures Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share.
Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are supplemental financial measures that are not required by, or presented in accordance with, GAAP. We believe that these non-GAAP measures, when taken together with our GAAP financial results, provide meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.
Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non- cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, our non-GAAP measures may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate these measures, limiting their usefulness as comparative measures. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share alongside other financial performance measures, including our net income, gross margin, and our other GAAP results. 5 We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We calculate Adjusted earnings per diluted share as net income per diluted share excluding the impact of stock-based compensation, adjusted for the associated impact of taxes. Please see Annex A: “Reconciliation of GAAP to Non-GAAP Financial Measures” elsewhere in this press release. For Further Information, Please Contact:
ASSETS September 30, December 31, Current assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 116,820 $ 112,238 equivalents Marketable securities 78,765 197,858 Accounts receivable, net of $54,156 and $55,659 of allowances 249,182 220,287 at September 30, 2026 and December 31, 2025, respectively Prepaid expenses and other current 19,634 21,392 assets Total current assets 464,401 551,775 Property and equipment, 50,252 29,927 net Operating lease 22,872 24,990 right-of-use assets Goodwill 19,832 19,978 Intangible assets, net 5,527 6,216 Deferred tax assets, 93,083 93,013 net Other noncurrent assets 19,826 16,536 Total assets $ 675,793 $ 742,435 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 148,001 $ 124,071 Accrued expenses and other current 92,038 78,320 liabilities Total current 240,039 202,391 liabilities Operating lease 21,726 24,000 noncurrent liabilities Total liabilities 261,765 226,391 Commitments and Contingencies STOCKHOLDERS' EQUITY Common stock, $0.0001 par value; 1,000,000,000 shares authorized; at September 30, 2026 and December 31, 2025, respectively; 9 9 100,087,996 and 99,049,485 shares issued; 74,723,072 and 83,365,696 outstanding at September 30, 2026 and December 31, 2025, respectively Additional paid-in 753,524 700,785 capital Treasury stock, at cost, $0.0001 par value; 25,980,904 and 16,299,769 shares -621,041 -388,075 at September 30, 2026 and December 31, 2025, respectively Accumulated earnings 281,363 202,827 Accumulated other 173 498 comprehensive income Total stockholders’ 414,028 516,044 equity Total liabilities and stockholders’ $ 675,793 $ 742,435 equity
Nine Months Ended September 30, OPERATING ACTIVITIES 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 78,536 $ 46,035 Adjustments to reconcile net income to net cash provided by operating activities: Deferred tax expense 29 31 Non-cash interest expense 591 279 Depreciation and 5,257 3,581 amortization Loss on disposal of property and 711 79 equipment Stock-based compensation 61,305 97,068 expense Bad debt expense 13,243 15,345 Net accretion of discounts on marketable 1,345 -432 securities Changes in operating assets and liabilities: Accounts receivable, net -42,161 -32,155 Prepaid expenses and other current 2,811 -14,859 assets Accounts payable 23,799 27,660 Accrued expenses and other current 11,900 13,317 liabilities Other noncurrent assets and -4,387 40 liabilities Net cash provided by operating 152,979 155,989 activities INVESTING ACTIVITIES Purchase of property and -21,931 -12,796 equipment, net Purchase of marketable -34,162 -311,513 securities Sale of marketable 151,222 166,380 securities Acquisition of business, net of cash — -9,340 acquired Net cash provided by (used in) investing 95,129 -167,269 activities FINANCING ACTIVITIES Repurchase of common stock -231,406 — Payment of excise tax from repurchase of -528 — common stock Proceeds from exercise of 38 23 stock options Issuance costs on credit — -3,087 facility Payment of employee taxes related to -12,563 -8,820 equity awards Proceeds from contributions to employee 1,051 781 stock purchase plan Net cash used in financing -243,408 -11,103 activities Effect of exchange rate changes on cash, -93 49 cash equivalents, and restricted cash Net increase (decrease) in cash, cash 4,607 -22,334 equivalents, and restricted cash Cash, cash equivalents, and restricted 114,193 162,314 cash, beginning of period Cash, cash equivalents, and restricted $ 118,800 $ 139,980 cash, end of period Cash and cash equivalents $ 116,820 $ 133,982 Restricted cash included within prepaid 1,054 — expenses and other current assets Restricted cash included within other 926 5,998 noncurrent assets Total cash, cash equivalents, and $ 118,800 $ 139,980 restricted cash SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid for income taxes, net of $ 32,643 $ 39,898 refunds received SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Additions of property and equipment, net included in accounts $ 2,399 $ 781 payable and accrued expenses Repurchases of common stock recorded in accrued expenses and other $ 1,501 $ — current liabilities Excise tax payable on common stock included in accrued $ 2,061 $ — expenses and other current liabilities Payment of employee taxes related to equity awards included in $ 291 $ 22 accrued expenses and other current liabilities
(in thousands, except share and per share amounts) Costs of Services, Gross Margin and Operating Expenses Excluding Stock-Based Compensation Calculation
The following table provides a reconciliation of cost of services, gross profit, sales and marketing and general and administrative expenses to each of these measures excluding the impact of stock-based compensation expense for each of the periods presented:
The following table provides a reconciliation of net income to Adjusted Earnings Per Diluted Share for each of the periods presented:
The following table provides a reconciliation of net income to Adjusted EBITDA for each of the periods presented:
11 Reconciliation of Non-GAAP Financial Guidance for the Three Months Ending December 31, 2026 and Year Ending December 31, 2026
* All of the numbers in the tables above reflect our future outlook as of the date hereof. Net income, Adjusted Net Income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity. 12 Assisted Reproductive Technology (ART) Cycles per Unique Female Utilizer
The following tables provide historical trend and guidance assumptions for average members, female utilization rate, and ART Cycles per Unique Female Utilizer for the full year and quarterly periods presented:
1 Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members from a single client not reflected in female utilizers as a result of the client's chosen benefit design.
2 Calculations exclude activity from a large client whose program discontinued for 2025, but who allowed for an extended period of transition of care for certain members during the first half of 2025.
*Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members from a single client not reflected in female utilizers as a result of the client's chosen benefit design.
Full text with the tables
Progyny, Inc. Announces Third Quarter 2026 Results
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA
and Net Income
Selling Season Yields Record 1.3 Million New Covered Lives with Another Year of
Near 100% Retention
Raises Midpoint of Full Year Guidance Ranges
NEW YORK, November 4, 2026 /GlobeNewswire/
- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in
women's health and family building solutions, today announced its financial
results for the three-month period ended September 30, 2026 (“the third quarter
of 2026”), as compared to the three-month period ended September 30, 2025 (“the
third quarter of 2025” or “the prior year period”).
“We're exceptionally pleased with the results of our most recent selling season,
where our momentum extended even into its latest stages, yielding 1.3 million
new covered lives, our most ever in a single season, and over 85 new clients,”
said Pete Anevski, Chief Executive Officer of Progyny. “Beyond new sales
activity, our season also focuses on renewing the existing base, where we once
again achieved a near 100% retention for 2027 as well as strong demand from
those accounts to expand their relationships with us through more comprehensive
coverage and the further adoption of our newest services in pregnancy, parenting
and menopause support.
“More than ever, these results once again affirm the critical importance of
these benefits to employers,” continued Anevski. “We believe the energy and
success we're seeing reflect how Progyny remains uniquely positioned to
consistently deliver meaningful value and cost trend control to employers, which
is particularly impactful given the pressures employers are facing from broader
medical cost inflation.
“As we look into next year, we believe we're well-positioned to extend this
momentum into 2027, as we're exiting the year with our strongest ever set-up in
terms of our number of opportunities and the overall size and quality of the
pipeline, as our demonstrated ability to effectively bend the cost curve
positions us well for continued success.”
“We achieved strong top- and bottom-line growth this quarter, reflecting that
member engagement was consistent with our expectations, and we are pleased to be
in a position to raise the midpoint of our full year guidance,” said Mark
Livingston, Chief Financial Officer of Progyny. “In addition to the strong
results this quarter, we continued to maintain a high conversion of Adjusted
EBITDA to operating cash flow, which has provided us with the flexibility to
continue investing in our platform while also returning value to shareholders
through the repurchase of nearly 11 million shares this year.”
Third Quarter 2026 Highlights:
(unaudited; in thousands,
except per 3Q 2026 3Q 2025
share amounts)
Revenue $341,254 $313,346
Gross Profit $83,740 $72,835
Gross Margin 24.5% 23.2%
Net Income $26,252 $13,864
Net Income per Diluted Share1 $0.32 $0.15
Adjusted Earnings per Diluted $0.52 $0.45
Share2
Adjusted EBITDA2 $58,439 $54,968
Adjusted EBITDA Margin2 17.1% 17.5%
Trailing Twelve-Month
Operating Cash $207,182 $208,153
Flow
1. Net income per diluted share reflects weighted-average shares outstanding as
adjusted for potential dilutive securities, including options, restricted stock
units, and shares issuable under the employee stock purchase plan .
1
2. Adjusted Earnings per Diluted Share, Adjusted EBITDA, and Adjusted EBITDA
margin are financial measures that are not required by, or presented in
accordance with U.S. generally accepted accounting principles ("GAAP"). Please
see Annex A of this press release for a reconciliation of Adjusted Earnings per
Diluted Share to earnings per share, and Adjusted EBITDA to net income, the most
directly comparable financial measures stated in accordance with GAAP for each
of the periods presented. We calculate Adjusted Earnings per Diluted Share as
net income per diluted share excluding the impact of stock-based compensation,
adjusted for the impact of taxes. We calculate Adjusted EBITDA margin as
Adjusted EBITDA divided by revenue.
Financial Highlights
Revenue was $341.3 million, an 8.9% increase as compared to the $313.3 million
reported in the third quarter of 2025, due to an increase in the number of
clients and covered lives.
• Fertility benefit services revenue was $223.4 million, a 10.6% increase from
the $201.9 million reported in the third quarter of 2025.
• Pharmacy benefit services revenue was $117.9 million, a 5.8% increase as
compared to the $111.4 million reported in the third quarter of 2025.
Gross profit was $83.7 million, an increase of 15% from the $72.8 million
reported in the third quarter of 2025, reflecting ongoing efficiencies realized
in the delivery of our care management services as well as a decrease in stock-
based compensation expense . Gross margin was 24.5%, as compared to 23.2%
reported in the prior year .
Net income was $26.3 million, or $0.32 income per diluted share, as compared to
the $13.9 million, or $0.15 income per diluted share, reported in the third
quarter of 2025. The higher net income was due primarily to the higher gross
profit and lower stock-based compensation expense, which was partially offset by
lower interest and other income, net.
Adjusted EBITDA was $58.4 million, an increase of 6.3% as compared to the $55.0
million reported in the third quarter of 2025, as the higher gross profit was
partially offset by planned investments to expand the features and functionality
of our platform . Adjusted EBITDA margin was 17.1% as compared to the 17.5%
Adjusted EBITDA margin in the third quarter of 2025. Refer to Annex A for a
reconciliation of Adjusted EBITDA to net income.
Cash Flow
Net cash provided by operating activities in the third quarter of 2026 was $56.6
million, as compared to $50.7 million in the prior year period. Cash flow
reflects the timing impact of certain working capital items in both periods.
Balance Sheet and Financial Position
As of September 30, 2026, the Company had total working capital of approximately
$224.4 million and no debt. This included cash and cash equivalents and
marketable securities of $195.6 million, a decrease of $41.3 million from the
balances as of June 30, 2026, as the operating cash flow generated was offset by
share repurchase activity during the quarter. The Company's $200 million
revolving credit facility remains undrawn, and the Company has no planned use
for the facility at this time.
Share Repurchase Activity
During the third quarter of 2026, the Company repurchased nearly 3 million
shares of its common stock for a total cost of $82.7 million through its May
2026 share repurchase program, which provided for a total authorization of up to
$200 million. To date, the Company has repurchased nearly 5.5 million shares of
its common stock under this most recent program, and approximately $51 million
remains under the existing authorization. In combination with its predecessor
program which began in November 2025 and concluded earlier this year, the
Company has now repurchased nearly 11 million shares thus far in 2026, and
approximately 14.3 million shares overall since November 2025.
Key Metrics
The Company had 607 fertility and family building clients as of September 30,
2026, as compared to 553 clients as of September 30, 2025.
2
Three Nine
Mont… Months
Ended Ended
Sept… Septe…
30, 30,
2026 2025 2026 2025
Ass…
Rep…
Tre… 16,7… 15,9… 49,3… 49,079
(AR…
Cyc…
Uti…
- 0.56% 0.54% 1.10% 1.06%
All
Mem…
Uti…
- 0.49% 0.47% 0.91% 0.88%
Fem…
Onl…
Ave… 7,17… 6,75… 7,16… 6,730…
Mem…
* Represents the number of ART cycles performed, including IVF with a fresh
embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers,
and egg freezing. Includes ART cycles performed in the first half of 2025 under
the extended transition of care agreement with the large client who did not
renew its service agreement.
** Represents the member utilization rate for all fertility and family building
services, including, but not limited to, ART cycles, initial consultations,
IUIs, and genetic testing. The utilization rate for all members includes all
unique members (female and male) who utilize the benefit during that period,
while the utilization rate for female only includes only unique females who
utilize the benefit during that period. For purposes of calculating utilization
rates in any given period, the results reflect the number of unique members
utilizing the benefit for that period. Individual periods cannot be combined as
member treatments may span multiple periods. Utilization for the nine month
period in 2025 excludes activity under the extended transition of care agreement
that ended June 30, 2025 with the large client who did not renew its service
agreement, as only members meeting certain criteria were eligible to use the
benefit.
***Includes approximately 300,000 members from a single client who are not
reflected in utilization as a result of the client's chosen benefit design. 2025
excludes the limited number of members who were eligible to use the benefit
under the extended transition of care agreement that ended June 30, 2025 with
the large client who did not renew its service agreement.
Financial Outlook
As the fourth quarter begins, member activity continues to remain healthy. In
light of the strong results over the first nine months of the year, as well as
our expectations for member engagement over the remainder of the year, we're
raising the midpoint of our full year guidance.
The majority of the clients and lives added in the most recent selling season
are expected to go live in the first quarter of 2027, though a meaningful number
of lives are expected to launch mid-year. In addition, a number of the newest
clients have already launched their benefit in 2026. Once all new clients are
live in 2027, the Company anticipates having in excess of 660 clients,
representing approximately 8.3 million covered lives.
As it relates to 2027, consistent with past practice, the Company anticipates
providing financial guidance when it reports its year-end results in February.
The Company is providing the following financial guidance for both the three-
month and full year periods ending December 31, 2026.
• Full Year 2026 Outlook:
o Revenue is projected to be $1.365 billion to $1.385 billion, reflecting growth
of 5.9% to 7.5%; excluding the $48.5 million of revenue in 2025 from the large
client who was under a transition agreement in the first half of 2025, revenue
is expected to increase by 10.1% to 11.7%
o Net income is projected to be $107.0 million to $110.6 million, or $1.30 to
$1.35 per diluted share, on the basis of approximately 82.0 million assumed
weighted-average fully diluted-shares outstanding
o Adjusted EBITDA 1 is projected to be $235.0 million to $240.0 million
o Adjusted earnings per diluted share 1 is projected to be $2.09 to $2.13
• Fourth Quarter of 2026 Outlook:
o Revenue is projected to be $344.7 million to $364.7 million, reflecting growth
of 8.3% to 14.6%
o Net income is projected to be $28.5 million to $32.1 million, or $0.36 to
$0.41 per diluted share, on the basis of approximately 79.0 million assumed
weighted-average fully diluted-shares outstanding
o Adjusted EBITDA 1 is projected to be $57.9 million to $62.9 million
o Adjusted earnings per diluted share 1 is projected to be $0.53 to $0.58
1. Adjusted EBITDA and Adjusted earnings per diluted share are financial
measures that are not required by, or presented in accordance with, GAAP. Please
see Annex A of this press release for a reconciliation of forward-looking
Adjusted EBITDA to forward-looking net
3
income and Adjusted net income to net income, the most directly comparable
financial measures stated in accordance with GAAP, for the period presented.
Conference Call Information
Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 p.m. Pacific
Time) today, November 4, 2026, to discuss its financial results. Interested
participants from the United States may join by calling 1.866.825.7331 and using
conference ID 265484. Participants from international locations may join by
calling 1.973.413.6106 and using the same conference ID. A replay of the call
will be available until November 11, 2026 at 5:00 p.m. Eastern Time by dialing
1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and
entering passcode 265484. A live audio webcast of the call and subsequent replay
will also be available through the Events & Presentations section of the
Company’s Investor Relations website at investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building
solutions, trusted by leading employers, health plans, and benefit purchasers
worldwide. Through its comprehensive and personalized approach, Progyny supports
members across fertility and family building, pregnancy and postpartum,
menopause and midlife, and parent and child well-being journeys. Progyny
combines differentiated clinical care, integrated pharmacy support through
Progyny Rx®, and personalized guidance from Progyny Care Advocates® to deliver
improved member experiences and better health outcomes. For more information,
visit www.progyny.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. We intend such forward-looking
statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All
statements contained in this press release other than statements of historical
fact, are forward-looking statements including, without limitation, statements
regarding our financial outlook for the fourth quarter and full year 2026,
including the impact of our sales season and client launches; our anticipated
number of clients and covered lives for 2026; our expected utilization rates and
mix; the demand for our solutions; our expectations for our selling season for
2027 launches; our positioning to successfully manage economic uncertainty on
our business; the timing of client decisions; our ability to retain existing
clients and acquire new clients; and our business strategy, plans, goals and
expectations concerning our market position, future operations, and other
financial and operating information. The words “anticipates,” “assumes,”
“believe,” “contemplate,” “continues, ” “could,” “estimates,” “expects,”
“future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,”
“should,” “target,” “will,” and the negative of these or similar expressions and
phrases are intended to identify forward-looking statements, though not all
forward-looking statements use these words or expressions.
Forward-looking statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be materially different
from any future results, performance or achievements expressed or implied by the
forward-looking statements. These risks include, without limitation, failure to
meet our publicly announced guidance or other expectations about our business;
competition in the market in which we operate; our history of operating losses
and ability to sustain profitability; unfavorable conditions in our industry or
the United States economy; our limited operating history and the difficulty in
predicting our future results of operations; our ability to attract and retain
clients and increase the adoption of services within our client base; the loss
of any of our largest client accounts; changes in the technology industry;
changes or developments in the health insurance market; negative publicity in
the health benefits industry; lags, failures or security breaches in our
computer systems or those of our vendors; a significant change in the
utilization of our solutions; our ability to offer high-quality support;
positive references from our existing clients; our ability to develop and expand
our marketing and sales capabilities; the rate of growth of our future revenue;
the accuracy of the estimates and assumptions we use to determine the size of
target markets; our ability to successfully manage our growth; reductions in
employee benefits spending; seasonal fluctuations in our sales; the adoption of
new solutions and services by our clients or members; our ability to innovate
and develop new offerings; our ability to adapt and respond to the changing
medical landscape,
4
regulations, and client needs, requirements or preferences; our ability to
maintain and enhance our brand; our ability to attract and retain members of our
management team, key employees, or other qualified personnel; risks related to
any litigation against us; our ability to maintain our Center of Excellence
network of healthcare providers; our strategic relationships with and monitoring
of third parties; our ability to maintain our pharmacy distribution network if
there is a disruption to our network or its associated supply chains; our
relationship with key pharmacy program partners or any decline in rebates
provided by them; our ability to maintain our relationships with benefits
consultants; exposure to credit risk from our members; risks related to
government regulation; risks related to our business with government entities;
our ability to protect our intellectual property rights; risks related to
acquisitions, strategic investments, or partnerships; federal tax reform and
changes to our effective tax rate; the imposition of state and local state
taxes; our ability to utilize a portion of our net operating loss or research
tax credit carryforwards; our ability to develop or maintain effective internal
control over financial reporting; and our ability to adapt and respond to the
changing SEC or stakeholder expectations regarding environmental, social and
governance practices. For a detailed discussion of these and other risk factors,
please refer to our filings with the Securities and Exchange Commission (the
“SEC”), including in the section entitled “Risk Factors” in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports
that we file with the SEC, which are available at http://investors.progyny.com
and on the SEC’s website at https://www.sec.gov .
Forward-looking statements represent our management’s beliefs and assumptions
only as of the date of this press release. Our actual future results could
differ materially from what we expect. Except as required by law, we assume no
obligation to update these forward-looking statements publicly, or to update the
reasons.
Non-GAAP Financial Measures
In addition to disclosing financial measures prepared in accordance with U.S.
generally accepted accounting principles (“GAAP”), this press release and the
accompanying tables include the non-GAAP financial measures Adjusted EBITDA,
Adjusted EBITDA margin, and Adjusted earnings per diluted share.
Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share
are supplemental financial measures that are not required by, or presented in
accordance with, GAAP. We believe that these non-GAAP measures, when taken
together with our GAAP financial results, provide meaningful supplemental
information regarding our operating performance and facilitates internal
comparisons of our historical operating performance on a more consistent basis
by excluding certain items that may not be indicative of our business, results
of operations or outlook. In particular, we believe that the use of Adjusted
EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share are
helpful to our investors as they are measures used by management in assessing
the health of our business, determining incentive compensation, evaluating our
operating performance, and for internal planning and forecasting purposes.
Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings per diluted share
are presented for supplemental informational purposes only, have limitations as
analytical tools and should not be considered in isolation or as a substitute
for financial information presented in accordance with GAAP. Some of the
limitations of Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted earnings
per diluted share include: (1) it does not properly reflect capital commitments
to be paid in the future; (2) although depreciation and amortization are non-
cash charges, the underlying assets may need to be replaced and Adjusted EBITDA
does not reflect these capital expenditures; (3) it does not consider the impact
of stock-based compensation expense; (4) it does not reflect other non-operating
income and expenses, including interest and other income, net; and (5) it does
not reflect tax payments that may represent a reduction in cash available to us.
In addition, our non-GAAP measures may not be comparable to similarly titled
measures of other companies because they may not calculate such measures in the
same manner as we calculate these measures, limiting their usefulness as
comparative measures. Because of these limitations, when evaluating our
performance, you should consider Adjusted EBITDA, Adjusted EBITDA margin, and
Adjusted earnings per diluted share alongside other financial performance
measures, including our net income, gross margin, and our other GAAP results.
5
We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and
amortization; stock-based compensation expense; interest and other income, net;
and provision for income taxes. We calculate Adjusted EBITDA margin as Adjusted
EBITDA divided by revenue. We calculate Adjusted earnings per diluted share as
net income per diluted share excluding the impact of stock-based compensation,
adjusted for the associated impact of taxes. Please see Annex A: “Reconciliation
of GAAP to Non-GAAP Financial Measures” elsewhere in this press release.
For Further Information, Please
Contact:
Investors:
James Hart
[email protected]
Media:
Alexis Ford
[email protected]
6
PROGYNY, INC.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
ASSETS September 30, December 31,
Current assets: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash $ 116,820 $ 112,238
equivalents
Marketable securities 78,765 197,858
Accounts receivable,
net of $54,156 and
$55,659 of allowances 249,182 220,287
at September 30,
2026 and December 31,
2025, respectively
Prepaid expenses and
other current 19,634 21,392
assets
Total current assets 464,401 551,775
Property and equipment, 50,252 29,927
net
Operating lease 22,872 24,990
right-of-use assets
Goodwill 19,832 19,978
Intangible assets, net 5,527 6,216
Deferred tax assets, 93,083 93,013
net
Other noncurrent assets 19,826 16,536
Total assets $ 675,793 $ 742,435
LIABILITIES AND
STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 148,001 $ 124,071
Accrued expenses and
other current 92,038 78,320
liabilities
Total current 240,039 202,391
liabilities
Operating lease 21,726 24,000
noncurrent liabilities
Total liabilities 261,765 226,391
Commitments and
Contingencies
STOCKHOLDERS' EQUITY
Common stock, $0.0001
par value;
1,000,000,000 shares
authorized; at
September 30, 2026 and
December 31,
2025, respectively; 9 9
100,087,996 and
99,049,485 shares
issued; 74,723,072 and
83,365,696 outstanding
at September 30,
2026 and December 31,
2025, respectively
Additional paid-in 753,524 700,785
capital
Treasury stock, at
cost, $0.0001 par
value; 25,980,904 and
16,299,769 shares -621,041 -388,075
at September 30, 2026
and December 31,
2025, respectively
Accumulated earnings 281,363 202,827
Accumulated other 173 498
comprehensive income
Total stockholders’ 414,028 516,044
equity
Total liabilities and
stockholders’ $ 675,793 $ 742,435
equity
7
PROGYNY, INC.
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
Three Nine
Months Months
Ended Ended
Septemb… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Reven… $ 341,254 $ 313,346 $ 1,020,2… $ 970,258
Cost
of 257,514 240,511 764,157 742,655
servi…
Gross 83,740 72,835 256,112 227,603
profit
Opera…
expen…
Sales
and 18,063 17,935 53,021 54,126
marke…
Gener…
and 30,495 33,373 92,527 103,422
admin…
Total
opera… 48,558 51,308 145,548 157,548
expen…
Income
from 35,182 21,527 110,564 70,055
opera…
Inter…
and
other 1,234 2,437 3,872 7,523
incom…
net
Income
before 36,416 23,964 114,436 77,578
income
taxes
Provi…
for 10,164 10,100 35,900 31,543
income
taxes
Net $ 26,252 $ 13,864 $ 78,536 $ 46,035
income
Net
income
per
share:
Basic $ 0.34 $ 0.16 $ 1.00 $ 0.54
Dilut… $ 0.32 $ 0.15 $ 0.95 $ 0.51
Weigh…
shares
used
in
compu…
net
income
per
share:
Basic 76,226,… 86,017… 78,400,… 85,780…
Dilut… 81,172,… 90,226… 82,726,… 89,884…
8
PROGYNY, INC.
Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Nine Months Ended
September 30,
OPERATING ACTIVITIES 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 78,536 $ 46,035
Adjustments to reconcile
net income to
net cash provided by
operating
activities:
Deferred tax expense 29 31
Non-cash interest expense 591 279
Depreciation and 5,257 3,581
amortization
Loss on disposal of
property and 711 79
equipment
Stock-based compensation 61,305 97,068
expense
Bad debt expense 13,243 15,345
Net accretion of discounts
on marketable 1,345 -432
securities
Changes in operating assets
and
liabilities:
Accounts receivable, net -42,161 -32,155
Prepaid expenses and other
current 2,811 -14,859
assets
Accounts payable 23,799 27,660
Accrued expenses and other
current 11,900 13,317
liabilities
Other noncurrent assets and -4,387 40
liabilities
Net cash provided by
operating 152,979 155,989
activities
INVESTING ACTIVITIES
Purchase of property and -21,931 -12,796
equipment, net
Purchase of marketable -34,162 -311,513
securities
Sale of marketable 151,222 166,380
securities
Acquisition of business,
net of cash — -9,340
acquired
Net cash provided by (used
in) investing 95,129 -167,269
activities
FINANCING ACTIVITIES
Repurchase of common stock -231,406 —
Payment of excise tax from
repurchase of -528 —
common stock
Proceeds from exercise of 38 23
stock options
Issuance costs on credit — -3,087
facility
Payment of employee taxes
related to -12,563 -8,820
equity awards
Proceeds from contributions
to employee 1,051 781
stock purchase plan
Net cash used in financing -243,408 -11,103
activities
Effect of exchange rate
changes on cash, -93 49
cash equivalents, and
restricted cash
Net increase (decrease) in
cash, cash 4,607 -22,334
equivalents, and restricted
cash
Cash, cash equivalents, and
restricted 114,193 162,314
cash, beginning of period
Cash, cash equivalents, and
restricted $ 118,800 $ 139,980
cash, end of period
Cash and cash equivalents $ 116,820 $ 133,982
Restricted cash included
within prepaid 1,054 —
expenses and other current
assets
Restricted cash included
within other 926 5,998
noncurrent assets
Total cash, cash
equivalents, and $ 118,800 $ 139,980
restricted cash
SUPPLEMENTAL DISCLOSURE OF
CASH FLOW
INFORMATION
Cash paid for income taxes,
net of $ 32,643 $ 39,898
refunds received
SUPPLEMENTAL DISCLOSURE OF
NON-CASH
INVESTING AND FINANCING
ACTIVITIES
Additions of property and
equipment, net
included in accounts $ 2,399 $ 781
payable and accrued
expenses
Repurchases of common stock
recorded in
accrued expenses and other $ 1,501 $ —
current
liabilities
Excise tax payable on
common stock
included in accrued $ 2,061 $ —
expenses and other
current liabilities
Payment of employee taxes
related to
equity awards included in $ 291 $ 22
accrued
expenses and other current
liabilities
9
ANNEX A
PROGYNY, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(in thousands, except share and per share amounts)
Costs of Services, Gross Margin and Operating Expenses Excluding Stock-Based
Compensation Calculation
The following table provides a reconciliation of cost of services, gross profit,
sales and marketing and general and administrative expenses to each of these
measures excluding the impact of stock-based compensation expense for each of
the periods presented:
T… …
M… …
E… …
S… …
3… …
2… …
──────────────────────────────────────────────────────────────────────────────
… S…
G… … N… … C… …
… E…
…
… $ 2… $ … $ 2… $ … $ -… $ …
…
… $ 8… $ … $ 9… $ … $ 9… $ …
…
…
… $ 1… $ … $ 1… $ … $ -… $ …
…
…
… $ 3… $ … $ 2… $ … $ -… $ …
…
…
…
a
…
…
…
… … % 1… % … % 2… % … % 2… %
…
…
… … % -… % … % 5… % … % 3… %
…
…
… … % -… % … % 1… % … % 5… %
…
N… …
M… …
E… …
S… …
3… …
2… …
… S…
G… … N… … C… …
… E…
…
… $ 7… $ … $ 7… $ … $ -… $ …
…
… $ 2… $ … $ 2… $ … $ 2… $ …
…
…
… $ 5… $ … $ 3… $ … $ -… $ …
…
…
… $ 9… $ … $ 6… $ … $ -… $ …
…
…
…
a
…
…
…
… … % 1… % … % 2… % … % 2… %
…
…
… … % -… % … % 5… % … % 3… %
…
…
… … % -… % … % 1… % … % 6… %
…
Note: percentages shown in the table may not cross foot due to rounding.
10
Adjusted Earnings Per Diluted Share Calculation
The following table provides a reconciliation of net income to Adjusted Earnings
Per Diluted Share for each of the periods presented:
Thr… Nine
mon… Mon…
end… Se… End… Se…
2026 30, 20… 2026 30, 20…
──────────────────────────────────────────────────────────────────────────────
N… $ 26… $ 13,… $ 78… $ 46,…
I…
A…
S…
c… 21,… 32… 61,… 97…
e…
I…
t…
e… -5,… -5… -10… -1…
of
n…
a…
A…
N… $ 42,… $ 40… $ 129… $ 12…
i…
D… 81… 90,… 82… 89,…
S…
A…
E…
P… $ 0.… $ 0.45 $ 1.… $ 1.42
D…
S…
Adjusted EBITDA Calculation
The following table provides a reconciliation of net income to Adjusted EBITDA
for each of the periods presented:
Thr… Nine
mon… Mon…
end… Se… End… Se…
2026 30, 20… 2026 30, 20…
──────────────────────────────────────────────────────────────────────────────
N… $ 26… $ 13,… $ 78… $ 46,…
i…
A…
D…
a… 2,… 1,2… 5,… 3,5…
a…
S…
c… 21,… 32… 61,… 97…
e…
I…
a…
o… -1,… -2… -3,… -7…
i…
n…
P…
f… 10,… 10… 35,… 31…
i…
t…
A… $ 58,… $ 54… $ 177… $ 17…
E…
11
Reconciliation of Non-GAAP Financial Guidance for the Three Months Ending
December 31, 2026 and Year Ending December 31, 2026
Thr…
Mon… Year
End… End…
Dec… Dec…
31, 31,
2026 2026
──────────────────────────────────────────────────────────────────────────────
Low High Low High
Re… $ 344… $ 364… $ 1,3… $ 1,38…
Net $ 28,… $ 32,… $ 107… $ 110,…
In…
Ad…
De…
and 2,7… 2,7… 8,0… 8,000
am…
St…
co… 18,… 18,… 79,… 79,5…
ex…
In…
and
ot… -2,… -2,… -6,… -6,3…
in…
net
Pr…
for 10,… 12,… 46,… 48,2…
in…
ta…
Ad… $ 57,… $ 62,… $ 235… $ 240,…
EB…
Three
Months Year
Ending Ending
December December
31, 2026 31, 2026
──────────────────────────────────────────────────────────────────────────────
Low High Low High
Net $ 28,464 $ 32,064 $ 107,000 $ 110,600
Income*
Add:
Stock-… 18,195 18,195 79,500 79,500
compen…
Income
tax
effect -4,500 -4,500 -15,100 -15,100
of
non-GA…
adjust…
Adjust…
Net $ 42,159 $ 45,759 $ 171,400 $ 175,000
income*
Diluted 79,000,… 79,000,… 82,000,… 82,000…
Shares
Adjust…
Earnin…
Per $ 0.53 $ 0.58 $ 2.09 $ 2.13
Diluted
Share
* All of the numbers in the tables above reflect our future outlook as of the
date hereof. Net income, Adjusted Net Income and Adjusted EBITDA ranges do not
reflect any estimate for other potential activities and transactions, nor do
they contemplate any discrete income tax items, including the income tax impact
related to equity compensation activity.
12
Assisted Reproductive Technology (ART) Cycles per Unique Female Utilizer
The following tables provide historical trend and guidance assumptions for
average members, female utilization rate, and ART Cycles per Unique Female
Utilizer for the full year and quarterly periods presented:
G…
A…
F…
Y…
E…
D…
3…
2…
──────────────────────────────────────────────────────────────────────────────
… L… H…
… E… E…
… as as
… of of
N… N…
… … … … … 4, 4,
2… 2…
… … … … … … …
… % … % … % … % … … …
… … … … … … …
… … … … … … …
… … … … … … …
… … … … … … …
1 Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members
from a single client not reflected in female utilizers as a result of the
client's chosen benefit design.
2 Calculations exclude activity from a large client whose program discontinued
for 2025, but who allowed for an extended period of transition of care for
certain members during the first half of 2025.
Quarterly ART Cycles per Unique Female Utilizer
Th…
Mo… Year
En… End…
──────────────────────────────────────────────────────────────────────────────
Ma… June Sep… Dec… Dec…
31, 30, 30, 31, 31,
2… 0.… 0.… 0.… 0.… 0.…
2… 0.… 0.… 0.… 0.… 0.…
2… 0.… 0.… 0.… 0.… 0.…
2… 0.… 0.… 0.… 0.… 0.…
2…
L…
E… 0.… 0.… 0.… 0.… 0.…
of
G…
R…
2…
H…
E… 0.… 0.… 0.… 0.… 0.…
of
G…
R…
*Calculations for 2024, 2025, and 2026 exclude approximately 300,000 members
from a single client not reflected in female utilizers as a result of the
client's chosen benefit design.
E indicates the estimated value assumed.
13